Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

3.38
+0.02500.75%
Volume:346.01K
Turnover:1.17M
Market Cap:50.70M
PE:-0.64
High:3.52
Open:3.35
Low:3.32
Close:3.35
Loading ...

BTIG Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)

TIPRANKS
·
12 Jul

BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Warner Music Group, GeneDx

Reuters
·
10 Jul

BUZZ-Jasper Therapeutics falls after halting clinical programs

Reuters
·
09 Jul

Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria

TIPRANKS
·
09 Jul

Jasper Therapeutics Inc - Estimates $1.8M-$2.2M in Severance Costs From Reorganization - SEC Filing

THOMSON REUTERS
·
09 Jul

Jasper Therapeutics Inc - Reducing Workforce by About 50%

THOMSON REUTERS
·
09 Jul

Jasper Therapeutics Inc - Daniel Adelman to Serve as Acting Chief Medical Officer

THOMSON REUTERS
·
09 Jul

Jasper Therapeutics Inc - Halting Other Clinical and Preclinical Programs, in Order to Focus on Development of Briquilimab in Chronic Urticaria

THOMSON REUTERS
·
09 Jul

Jasper Therapeutics Inc: No Longer Plans to Initiate Additional Mast Cell Focused Clinical Development Program This Year

THOMSON REUTERS
·
09 Jul

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

THOMSON REUTERS
·
09 Jul

Press Release: Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Dow Jones
·
09 Jul

Jasper Therapeutics Inc : Bmo Cuts to Market Perform From Outperform; Cuts Target Price to $4 From $15

THOMSON REUTERS
·
08 Jul

Jasper Therapeutics (JSPR) Receives a Buy from Evercore ISI

TIPRANKS
·
08 Jul

TD Cowen Sticks to Their Buy Rating for Jasper Therapeutics (JSPR)

TIPRANKS
·
08 Jul

Jasper Therapeutics downgraded to Market Perform from Outperform at BMO Capital

TIPRANKS
·
08 Jul

Hold Rating for Jasper Therapeutics Amid Uncertainties in Briquilimab’s Clinical Trials and Competitive Challenges

TIPRANKS
·
08 Jul

Jasper Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
08 Jul

Jasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
08 Jul

Buy Rating Maintained for Jasper Therapeutics Amid Manufacturing Setback and Promising Drug Profile

TIPRANKS
·
08 Jul

BUZZ-U.S. STOCKS ON THE MOVE-U.S. Bancorp, IonQ, BlackRock

Reuters
·
08 Jul